[Edaily Reporter Kwon Oh-seok] #Aptabio announced on the 16th that it has received approval from the U.S. Food and Drug Administration (FDA) to lift the clinical hold and resume Phase 1 clinical trials for "ABF-101," an oral treatment for age-related macular degeneration. Following receipt of this official notice, the company plans to resume the previously suspended clinical trials and drug administration.
Disclosure Plus
Aptabio Lifts Hold on Phase 1 Clinical Trial for 'ABF-101'
Economy
Corporation
IT·Science
Economy
[Breaking News] LGELECTRONICS Reports 1.5788 Trillion Won in Second-Quarter Operating Profit… Up 146.9% Year-Over-Year
LGELECTRONICS announced on the 8th that it recorded consolidated preliminary results for the second quarter of this year, with revenue of 23.8297 trillion won and operating profit of 1.5788 trillion w…
Corporation
MEDIANA Co.,LTD partners with FuriosaAI and XY to Develop 'Hospital-Based Physical AI'
MEDIANA Co.,LTD(041920)is partnering with AI semiconductor company FuriosaAI and AI robotics specialist XYZ to build a hospital-based Physical AI platform. This move is seen as a strategic shift away …
IT·Science
CrowdWorks, Inc. Wins Contract for AI Hub Inference Data Project
CrowdWorks, Inc.(355390)has been awarded a contract to build training data aimed at enhancing artificial intelligence (AI)’s ability to understand Korean context and perform logical reasoning. The pro…
